To observe the effect of Unani medicines on certain Biochemical markers like VEGF-A, VEGF-C and inflammatory cytokines in patients of Lymphatic Filariasis (Daul Feel)

Evaluation of certain Unani Formulations on VEGFs and inflammatory cytokines in Lymphatic Filariasis (Daul Feel)

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2015/03/005611

Enrollment

Registered

2015-03-05

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B740- Filariasis due to Wuchereria bancrofti Health Condition 2: null- Lymphatic Filariasis (Daul Feel)

Interventions

Intervention1: UNIM 268 with UNIM 270 plus UNIM-272 & UNIM 271: DOSE UNIM 268 Two tablets 500 mg each twice daily with water on empty stomach for 80 days UNIM 270 plus UNIM 272 UNIM 270 ie 10 gms p

Eligibility

Inclusion criteria

Inclusion criteria: The patients of either sex in the age group of 18 to 65 years having limb lymphoedema with the presence or history of the following symptoms and signs will be included in the study. i. Fever with or without Rigors ii. Lymphadenitis iii. Lymphangitis(AFL) iv. Unilateral Lower Limb Lymphoedema v. Funiculo-Epididymo-Orchitis vi. Hydrocoele vii. Chyluria viii. Other Associated Features Urticaria, Headache, Malaise, Nausea, Vomiting, Anorexia

Exclusion criteria

Exclusion criteria: The patients of lymphatic filariasis having following conditions will be excluded from the study. i. Patients below 18 years and above 65 years of age ii. Pregnant Women and Lactating Mothers iii. Patients with Complications iv. Patients with other Concomitant Diseases v. Patients on Treatment with other Drugs vi. Malnourished Patients vii. Patients not willing to provide informed consent and to report for follow-up

Design outcomes

Primary

Measure	Time frame
Modulation of VEGFs and Cytokines, point out the therapeutic efficacy of Unani formulationTimepoint: Three months fifteen days	—

Secondary

Measure	Time frame
Understanding the biochemical and immunological profile of Lymphoedema (and hydrocele) will help us to develop better methods of identifying persons at risk, and preventing â?? ameliorating these severe pathologies, thus improving the daily lives of the affected individualsTimepoint: Three months fifteen days	—

Countries

India

Contacts

Public ContactDR PRADEEP KUMAR

Central Council for Research in Unani Medicine (CCRUM)

ccrum507@gmail.com9810161758

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026